SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Omer Shvili who wrote (577)3/2/1999 9:56:00 PM
From: arnie h  Read Replies (3) of 1386
 
Omer:

>I also agree that the ophthalmic line doesn't excite most people. I think it's a great product line, which will be able to support a $6 stock by 2001 (with $0.25 - $0.30 EPS), even if HU211 fails on PIII, so I am excited. It's no blockbuster, but it gets the job done, and if I get a +200% return in the coming 2 years, I'll be happy.>

Just wondering what the the basis is for your optimism on the outlook for the ophthalmic line. BOL sales to date have been growing at glacial speed and I've seen no projection from the company that indicates any increase in the rather tedious pace of sales growth. Would appreciate any perspectives you have on the pace of PARS revenues from this line.

Thanks,
Arnie
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News